Page 388 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
accruing
patients on the
AS protocol in
the early yr.
Generally,
patients with a
Gleason score
≤7 and stage
≤T2b were
offered AS.
Over the yr the
inclusion criteria
became
narrower, i.e.
Gleason score
≤6, PSA ≤15
ng/mL, stage
≤T2 and low-
volume disease
(≤50% of two
biopsy cores).
Slightly changes
in eligibility
criteria,
reported in
Soloway
2010 123 and
Gorin 2011: 122
AS is offered to
prostate cancer
patients with
PSA ≤10
ng/mL, Gleason
score ≤6, ≤2
positive biopsy
cores with
tumor ≤20% in
each core,

C-112